Related Experiment Videos
[Methadone and sleep apnea syndrome]
Philippe Durst1, Jérôme Palazzolo, Jean-Pierre Peyrelong
1Centre Hospitalier Sainte Marie, Réseau ERAHSM, Privas, France.
Summary
Central sleep apnea (CSA) can occur during opiate withdrawal. This case study highlights risks associated with benzodiazepine use in patients undergoing methadone treatment for opioid dependence.
Area of Science:
- Sleep Medicine
- Neurology
- Pharmacology
Background:
- Sleep apnea syndrome is characterized by recurrent breathing cessation during sleep.
- Symptoms include loud snoring, disrupted sleep, and excessive daytime sleepiness.
- Central sleep apnea (CSA) involves a lack of respiratory effort during apneic events.
Observation:
- This article details a case of CSA in a female patient undergoing opiate replacement therapy.
- The patient was receiving methadone for opioid dependence.
- Polysomnographic data before and after methadone withdrawal were analyzed.
Findings:
- Methadone withdrawal was associated with the onset or exacerbation of central sleep apnea.
- The study critically examines the etiology and pathophysiology of CSA in this context.
- Analysis revealed significant changes in respiratory patterns post-methadone withdrawal.
Implications:
- Clinicians must exercise caution when managing sleep disorders in patients on opiate replacement therapy.
- Prescribing benzodiazepines during methadone withdrawal is contraindicated in cases of central apnea.
- This finding underscores the importance of careful medication management to avoid adverse respiratory events.